New antibiotic agents and approaches to treat biofilm-associated infections

Bibliography

• Karatan E, Watnick P. Signals, regulatory networks, and materials that build and break bacterial biofilms. Microbiol Mol Biol Rev 2009;73(2):310-47
   Google Scholar
• Haussler S, Parsek MR. Biofilms 2009: new perspectives at the heart of surface-associated microbial communities. J Bacteriol 2010;192(12):2941-9
   Google Scholar
• Lewis K. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 2008;322:107-31
   PubMed Web of Science ®Google Scholar
• Anderson GG, O'Toole GA. Innate and induced resistance mechanisms of bacterial biofilms. Curr Top Microbiol Immunol 2008;322:85-105
   PubMed Web of Science ®Google Scholar
• Jayaraman R. Bacterial persistence: some new insights into an old phenomenon. J Biosci 2008;33(5):795-805
   Google Scholar
• Hoiby N, Bjarnsholt T, Givskov M, Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010;35(4):322-32
   PubMed Web of Science ®Google Scholar
• Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15(2):167-93
   PubMed Web of Science ®Google Scholar
• Parsek MR, Singh PK. Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol 2003;57(1):677-701
   Google Scholar
• Falagas ME, Kapaskelis AM, Kouranos VD, Outcome of antimicrobial therapy in documented biofilm-associated infections: a review of the available clinical evidence. Drugs 2009;69(10):1351-61
   Google Scholar
• Utili R, Durante-Mangoni E, Tripodi M-F. Infection of intravascular prostheses: how to treat other than surgery. Int J Antimicrob Agents 2007;30(Suppl 1):42-50
   Google Scholar
• Baddour LM, Wilson WR, Bayer AS, Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, American heart association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111(23):e394-434
   Google Scholar
• Samuel JR, Gould FK. Prosthetic joint infections: single versus combination therapy. J Antimicrob Chemother 2010;65(1):18-23
   PubMed Web of Science ®Google Scholar
• Matthews PC, Berendt AR, McNally MA, Byren I. Diagnosis and management of prosthetic joint infection. BMJ 2010;338:1378-83
   Google Scholar
• Agarwal A, Singh KP, Jain A. Medical significance and management of staphylococcal biofilm. FEMS Immunol Med Microbiol 2010;58(2):147-60
   Google Scholar
• Lynch AS, Robertson GT. Bacterial and fungal biofilm infections. Annu Rev Med 2008;59:415-28
   PubMed Web of Science ®Google Scholar
• Nguyen HM, Graber CJ. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother 2010;65(1):24-36
   Google Scholar
• Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage. WO2006130629; 2006
   Google Scholar
• Targanta Therapeutics Corp. Methods using glycopeptide antibiotics for inhibiting and treating biofilms and bacterial infections caused by bacteria that exhibit tolerance to antimicrobial agents. WO2009126502; 2009
   Google Scholar
• Cumbre Pharmaceuticals, Inc. Quinolone carboxylic acid-substituted rifamycin derivatives. US20090143373; 2009
   Google Scholar
• Renick PJ, Morris TW, Nguyen PM, Efficacy of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, in rodent models of bacterial infection. Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2007
   Google Scholar
• Xiong YQ, Weiss WJ, Doyle TB, Efficacy of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, and vancomycin in experimental methicillin-resistant Staphylococcus aureus infective endocarditis. Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2007
   Google Scholar
• Xiong YQ, Weiss WJ, Doyle TB, Comparative efficacy of CBR-2092 and conventional rifampin+quinolone combinations in experimental infective endocarditis caused by a quinolone-resistant MRSA. Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2007
   Google Scholar
• Torres-Viera C, Thauvin-Eliopoulos C, Souli M, Activities of taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2000;44(6):1720-4
   Google Scholar
• Polaschegg, Hans-Dietrich. Taurolidine formulations for antimicrobial protection against bacterial biofilm formation. WO2005115357; 2005
   Google Scholar
• Nagl M, Hess MW, Pfaller K, Bactericidal activity of micromolar N-chlorotaurine: evidence for its antimicrobial function in the human defense system. Antimicrob Agents Chemother 2000;44(9):2507-13
   Google Scholar
• Novacal Pharmaceutical, Inc. System and method for the prevention of bacterial and fungal infections including urinary tract infections using N-halogenated amino acids. WO2007044559; 2007
   Google Scholar
• Fang FC. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 1997;100(Suppl 12):S43-50
   Google Scholar
• Hetrick EM, Shin JH, Paul HS, Schoenfisch MH. Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles. Biomaterials 2009;30(14):2782-9
   Google Scholar
• Raulli R, McElhaney-Feser G, Hrabie JA, Cihlar RL. Antimicrobial properties of nitric oxide using diazeniumdiolates as the nitric oxide donor. Recent Res Dev Microbiol 2002;6(Pt 1):177-83
   Google Scholar
• Barraud N, Hassett DJ, Hwang S-H, Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol 2006;188(21):7344-53
   Google Scholar
• Environmental Biotechnology CRC. Methods and compositions for regulating biofilm development. WO2006125262; 2006
   Google Scholar
• Enox Biopharma, Inc. Biofilm-inhibiting catheters and tubings. WO2009124379; 2009
   Google Scholar
• Central Northern Adelaide Health Service and The Queen Elizabeth Hospital Research Foundation, Inc. Methods and compositions inhibiting sialic acid-mediated adhesion for treating pathological infections. WO2009155665; 2009
   Google Scholar
• Soong G, Muir A, Gomez MI, Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production. J Clin Invest 2006;116(8):2297-305
   Google Scholar
• The Trustees of Columbia University, USA. Neuraminidase inhibitors and uses thereof. WO2008054475; 2008
   Google Scholar
• Manetti AGO, Zingaretti C, Falugi F, Streptococcus pyogenes pili promote pharyngeal cell adhesion and biofilm formation. Mol Microbiol 2007;64(4):968-83
   Google Scholar
• Svensson A, Larsson A, Emtenas H, Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. ChemBioChem 2001;2(12):915-18
   Google Scholar
• Emtenaes H, Ahlin K, Pinkner JS, Design and parallel solid-phase synthesis of ring-fused 2-pyridinones that target pilus biogenesis in pathogenic bacteria. J Comb Chem 2002;4(6):630-9
   Google Scholar
• Washington University, USA. Preparation of fused aminomethylpyridinones as bacterial adhesion inhibitors. US2007082887; 2007
   Google Scholar
• Conrady DG, Brescia CC, Horii K, A zinc-dependent adhesion module is responsible for intercellular adhesion in staphylococcal biofilms. Proc Natl Acad Sci USA 2008;105(49):19456-61
   Google Scholar
• Weinberg ED. Suppression of bacterial biofilm formation by iron limitation. Med Hypotheses 2004;63(5):863-5
   Google Scholar
• University of Cincinnati, USA. Zinc chelators to inhibit biofilm formation. WO2009155088; 2009
   Google Scholar
• Rogers SA, Huigens RW III, Melander C. A 2-aminobenzimidazole that inhibits and disperses Gram-positive biofilms through a zinc-dependent mechanism. J Am Chem Soc 2009;131(29):9868-9
   Google Scholar
• Novartis AG. Triazoles for treating biofilm formation. WO2008142094; 2008
   Google Scholar
• University of Washington, USA; Hadassah Medical Organization. Metallo-desferrioxamine complexes and their use in the treatment of bacterial infections. US2008085866; 2008
   Google Scholar
• The Trustees of the University of Pennsylvania, USA. Biofilm prevention using lactoferrin. WO2009009065; 2009
   Google Scholar
• Baldoni D, Steinhuber A, Zimmerli W, Trampuz A. In vitro activity of gallium maltolate against staphylococci in logarithmic, stationary, and biofilm growth phases: comparison of conventional and calorimetric susceptibility testing methods. Antimicrob Agents Chemother 2010;54(1):157-63
   Google Scholar
• Kaneko Y, Thoendel M, Olakanmi O, The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest 2007;117(4):877-88
   PubMed Web of Science ®Google Scholar
• Titan Pharmaceuticals, Inc. Use of gallium-containing compositions to treat biofilm-associated infections. WO2007087461; 2007
   Google Scholar
• Williams JD. Antimicrobial chemotherapy – today. First International Moxifloxacin Symposium; 2000. p. 7-11
   Google Scholar
• Mbec Bioproducts, Inc. The use of heavy metals in the treatment of biofilms. WO2005122773; 2005
   Google Scholar
• Burne RA, Chen Y-YM. Bacterial ureases in infectious diseases. Microb Infect 2000;2(5):533-42
   Google Scholar
• Kruszewska D. Alpha-ketoglutarate for medical conditions related to the presence or activity of ureolytic bacteria. WO2009005379; 2009
   Google Scholar
• Texas Tech University, USA. Compositions and methods for activation and inhibition of Staphylococcus aureus biofilm development. US2008241281; 2008
   Google Scholar
• North Carolina State University, USA. Preparation imidazole-triazole derivatives that inhibit and disperse bacterial biofilms. US2009263438; 2009
   Google Scholar
• Martin RG, Rosner JL. The AraC transcriptional activators. Curr Opin Microbiol 2001;4(2):132-7
   Google Scholar
• Wall ME, Markowitz DA, Rosner JL, Martin RG. Model of transcriptional activation by MarA in Escherichia coli. PLoS Comp Biol 2009;5(12):e1000614
   Google Scholar
• Paratek Pharmaceuticals, Inc. Preparation of benzoimidazole compounds as transcription factor modulating compounds to treat infections. WO2008130368; 2008
   Google Scholar
• Verschueren KHG, Addy C, Dodson EJ, Wilkinson AJ. Crystallization of full-length CysB of Klebsiella aerogenes, a LysR-type transcriptional regulator. Acta Crystallogr D Biol Crystallogr 2001;57(2):260-2
   Google Scholar
• Ren D, Zuo R, Gonzalez Barrios AF, Differential gene expression for investigation of Escherichia coli biofilm inhibition by plant extract ursolic acid. Appl Environ Microbiol 2005;71(7):4022-34
   Google Scholar
• Sequoia Sciences, Inc. Inhibition of biofilm formation. US7604978; 2009
   Google Scholar
• Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor. US2006228384; 2006
   Google Scholar
• Landini P, Antoniani D, Burgess JG, Nijland R. Molecular mechanisms of compounds affecting bacterial biofilm formation and dispersal. Appl Microbiol Biotechnol 2010;86(3):813-23
   Google Scholar
• Pan J, Ren D. Quorum sensing inhibitors: a patent overview. Expert Opin Ther Patents 2009;19(11):1581-601
   Google Scholar
• Raina S, De Vizio D, Odell M, Microbial quorum sensing: a tool or a target for antimicrobial therapy? Biotechnol Appl Biochem 2009;54(2):65-84
   Google Scholar
• Waters CM, Bassler BL. Quorum sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev Biol 2005;21:319-46
   PubMed Web of Science ®Google Scholar
• The Trustees of Princeton University, USA. Inhibition of quorum sensing-mediated processes in bacteria using antagonists of the autoinducer-1-binding site of Vibrio harveyi sensory kinase LuxN. WO2009148571; 2009
   Google Scholar
• Biosignal Ltd. Preparation of furanone derivatives as antibacterial agents. WO2008040097; 2008
   Google Scholar
• Biosignal Ltd. Lactams, processes for preparing them, pharmaceutical compositions containing them, and their use as antibacterial agents. WO2007085042; 2007
   Google Scholar
• Suga H, Igarashi J. Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same. US2009068120; 2009
   Google Scholar
• University of Iowa Research Foundation, USA. Agr-mediated inhibition and dispersal of biofilms. WO2009154988; 2009
   Google Scholar
• Balaban N, Braunstein J. Bone cement compositions and the like comprising an RNAIII-inhibiting peptide. US2007092572; 2007
   Google Scholar
• Tamayo R, Pratt JT, Camilli A. Roles of cyclic diguanylate in the regulation of bacterial pathogenesis. Annu Rev Microbiol 2007;61:131-48
   PubMed Web of Science ®Google Scholar
• Ishihara Y, Hyodo M, Hayakawa Y, Effect of cyclic bis(3′-5′)diguanylic acid and its analogs on bacterial biofilm formation. FEMS Microbiol Lett 2009;301(2):193-200
   Google Scholar
• University of Maryland, USA. Method for attenuating virulence of microbial pathogens and inhibiting microbial biofilm formation by using c-di-GMP and cyclic dinucleotide analogs. WO2005030186; 2005
   Google Scholar
• Smart Assays. Preparation of non-hydrolyzable and permeable cyclic bis-(nucleotide monophosphate) derivatives as antibacterial agents. WO2009133560; 2009
   Google Scholar
• Davies DG, Marques CNH. A fatty acid messenger is responsible for inducing dispersion in microbial biofilms. J Bacteriol 2009;191(5):1393-403
   Google Scholar
• Research Foundation of State University of New York, USA. Induction of a physiological dispersion response in bacterial cells in a biofilm. WO2008143889; 2008
   Google Scholar
• Ni N, Li M, Wang J, Wang B. Inhibitors and antagonists of bacterial quorum sensing. Med Res Rev 2009;29(1):65-124
   Google Scholar
• Hoiby N. Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. J Cyst Fibros 2002;1(4):249-54
   Google Scholar
• Algipharma IPR AS. Alginate oligomers in combating biofilms. WO2009068841; 2009
   Google Scholar
• Giltner CL, van Schaik EJ, Audette GF, The Pseudomonas aeruginosa type IV pilin receptor binding domain functions as an adhesin for both biotic and abiotic surfaces. Mol Microbiol 2006;59(4):1083-96
   Google Scholar
• The Regents of the University of Colorado, USA; University of Alberta, Canada. Non-toxic biofilm inhibitor. WO2007089272; 2007
   Google Scholar
• Institut Pasteur, Fr.; Centre National De La Recherche Scientifique. Bacterial capsular polysaccharides that inhibit biofilm formation and growth. EP1872791; 2008
   Google Scholar
• Baehni PC, Takeuchi Y. Anti-plaque agents in the prevention of biofilm-associated oral diseases. Oral Dis 2003;9(Suppl 1):23-9
   Google Scholar
• Sinclair Pharmaceuticals Ltd. Use of morpholino compounds for the prevention of bacterial contamination. WO2006082393; 2006
   Google Scholar
• Kim JW, Huh JE, Kyung SH, Kyung KH. Antimicrobial activity of alk(en)yl sulfides found in essential oils of garlic and onion. Food Sci Biotechnol 2004;13(2):235-9
   Google Scholar
• Zentz F, Valla A, Le Guillou R, Synthesis and antimicrobial activities of N-substituted imides. Farmaco 2002;57(5):421-6
   Google Scholar
• Kane Biotech, Inc. Synergistic antimicrobial compositions and methods for reducing biofilm formation on medical devices. US7144992; 2006
   Google Scholar
• Cerca N, Jefferson KK, Oliveira R, Comparative antibody-mediated phagocytosis of Staphylococcus epidermidis cells grown in a biofilm or in the planktonic state. Infect Immun 2006;74(8):4849-55
   Google Scholar
• Hetrick EM, Schoenfisch MH. Reducing implant-related infections: active release strategies. Chem Soc Rev 2006;35(9):780-9
   PubMed Web of Science ®Google Scholar
• Van Houdt R, Michiels CW. Role of bacterial cell surface structures in Escherichia coli biofilm formation. Res Microbiol 2005;156(5-6):626-33
   Google Scholar
• Ma L, Jackson KD, Landry RM, Analysis of Pseudomonas aeruginosa conditional Psl variants reveals roles for the Psl polysaccharide in adhesion and maintaining biofilm structure postattachment. J Bacteriol 2006;188(23):8213-21
   Google Scholar
• Maira-Litran T, Kropec A, Abeygunawardana C, Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide. Infect Immun 2002;70(8):4433-40
   Google Scholar
• Shahrooei M, Hira V, Stijlemans B, Inhibition of Staphylococcus epidermidis biofilm formation by rabbit polyclonal antibodies against the SesC protein. Infect Immun 2009;77(9):3670-8
   Google Scholar
• Stichting Katholieke Universiteit; Radboud University Nijmegen Medical Centre; Katholieke Universiteit Leuven. Preventing and treating staphylococcus biofilm formation by using antibodies to and vaccines comprising SE2232 or its LPxTG motif-containing homolog. WO2008127099; 2008
   Google Scholar
• Park J, Jagasia R, Kaufmann GF, Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol 2007;14(10):1119-27
   PubMed Web of Science ®Google Scholar
• Haptogen Ltd. Methods for reducing biofilm formation by infectious bacteria. WO2005111080; 2005
   Google Scholar
• Flemming H-C, Neu TR, Wozniak DJ. The EPS matrix: the “house of biofilm cells”. J Bacteriol 2007;189(22):7945-7
   Google Scholar
• Kane Biotech, Inc. Dispersin Btm, 5-fluorouracil, deoxyribonuclease I and proteinase K-based antibiofilm compositions and for inhibiting growth and formation of biofilms. WO2009121183; 2009
   Google Scholar
• Prothera, Inc. Oral anti-biofilm compositions for inhibition and treatment of gastrointestinal biofilms. WO2009100456; 2009
   Google Scholar
• Boston University, USA; Massachusetts Institute of Technology, USA. Engineered enzymatically active bacteriophage expressing biofilm-degrading enzymes, such as dispersin B, and methods for dispersing bacterial biofilms. US2009155215; 2009
   Google Scholar
• Fox JL. Proponents: PET imaging could expand role in diagnosing infections. Microbe 2010;5(1):2010
   Google Scholar